Akademik Veri Yönetim Sistemi
ISPBS-6 -THE SIXTH INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL AND BIOMEDICAL SCIENCES, Gaziantep, Türkiye, 26 - 28 Mayıs 2022, cilt.1, ss.70
Abstract
One of the widely known side effects of nifedipine is gingival overgrowth. The aim of this study
is method development for determination of nifedipine concentration in gingival crevicular
fluid (GCF) and plasma by HPLC, and to determine whether there is a relationship between
plasma and GCF nifedipine levels.
Separation of nifedipine from GCF was performed by Microsphere, C18 (100 x 4.6 mm, particle
size 3 μm) analytical column and methanol, sodium acetate (pH=4.0, 10 mM) (60:40, v/v)
containing mobile phase at 0.8 ml/min. Detection of nifedipine and nitrendipine (internal
standard, 0.5 μg/ml) was performed by UV/Vis detector at 235 nm. GCF samples were
extracted by using a mixture of methanol and water (50:50, v/v). Plasma nifedipine content
were extracted by using a mixture of hexane and dichloromethane. The calibration curve for
nifedipine was linear over the concentration range of 0.01-0.5 μg/ml. The mean recovery (±SD)
from GCF was 99.05±3.72 % for nifedipine at a concentration of 0.1 μg/ml (n=6). The mean
recovery (±SD) from plasma was 102.03±5.62 % for nifedipine at a concentration of 0.1 μg/ml
(n=6).
No association was found between GCF and plasma levels, and nifedipine is not a risk factor
for gingival enlargement. Consequently, this study describes a simple, sensitive, and practical
HPLC-UV/Vis method which permits determination of nifedipine in human gingival crevicular
fluid and plasma samples.